Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas

  • STATUS
    Recruiting
  • End date
    Jul 31, 2025
  • participants needed
    36
  • sponsor
    Washington University School of Medicine
Updated on 24 January 2021
platelet count
stem cell transplantation
hodgkin's disease
cytarabine
melphalan
cell transplantation
gilbert's syndrome
etoposide
neutrophil count
autograft
carmustine
b-cell lymphoma
peripheral t-cell lymphoma
anaplastic large cell lymphoma
large cell lymphoma

Summary

The investigators hypothesize that duvelisib maintenance after autologous stem cell transplant with carmustine, etoposide, cytarabine, and melphalan (BEAM) conditioning in patients with T-cell lymphomas, or a history of indolent B-cell lymphomas, will be safe and well tolerated, and will improve progression free survival.

Details
Condition Lymphoma, T-Cell Lymphoma, Non-Hodgkin's Lymphoma, Indolent B Cell Lymphoma, t cell lymphoma
Treatment Peripheral blood draw, duvelisib
Clinical Study IdentifierNCT04331119
SponsorWashington University School of Medicine
Last Modified on24 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: T-Cell Lymphoma or Indolent B Cell Lymphoma or Non-Hodgkin's Lymphoma or Lymphoma?
Do you have any of these conditions: t cell lymphoma or Non-Hodgkin's Lymphoma or T-Cell Lymphoma or Indolent B Cell Lymphoma or Lymphoma?
Diagnosis of T cell non-Hodgkin lymphoma, or indolent B cell non-Hodgkin lymphoma. B-cell histologies include follicular, CLL/SLL, lymphoplasmacytic, or marginal zone lymphomas, and include transformed to aggressive B-cell lymphoma. T cell lymphomas included are peripheral T cell lymphoma not otherwise specified, angioimmunoblastic T cell lymphoma, and systemic anaplastic large cell lymphoma
Eligible for autologous stem cell transplantation as determined by the treating physician or completed BEAM autologous transplant within the last 30 days
At least 18 years of age at time of enrollment
Eastern Cooperative Oncology Group (ECOG) performance status 2
Adequate organ function as defined below
Serum creatinine 1.5 times institutional upper limit of normal (IULN)
Total bilirubin 1.5 x IULN. Patients with Gilbert's Syndrome may have a bilirubin > 1.5 x IULN
Hemoglobin 8.0 g/dL
Absolute neutrophil count 1.0 x 109/L
Platelet count 75 x 109/L
AST(SGOT)/ALT(SGPT) 3.0 x IULN
Women of childbearing potential and men must agree to use highly effective contraception prior to study entry and for the duration of study participation and for 3 months after the last dose of duvelisib. Negative serum human chorionic gonadotropin (HCG) pregnancy test within 7 days before first treatment is required if the patient is a woman of childbearing potential
Participants or a participant's legally authorized representative must be able to understand and willing to sign an IRB approved written informed consent document

Exclusion Criteria

Currently receiving any other experimental therapy or has received experimental therapy within 4 weeks prior to study treatment
History of allergic reaction attributed to compounds of similar chemical or biologic composition to duvelisib or other agents used in the study
Prior history of drug-induced colitis or drug-induced pneumonitis
History of concurrent interstitial lung disease or severely impaired lung function
History of chronic liver disease or veno-occlusive disease
History of tuberculosis within 2 years prior to enrollment
Administration of a live or live attenuated vaccine within 6 weeks of first duvelisib dose
Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine) or systemic steroids > 20 mg of prednisone (or equivalent) per day
Ongoing treatment for systemic bacterial, fungal, or viral infections at screening
Note: patients on antimicrobial, antifungal, or antiviral prophylaxis are not
specifically excluded is all other inclusion/exclusion criteria are met
Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV), or herpes zoster (VZV) at screening
Infection with HBV, HCV. Subjects with a positive HBsAg or HCV Ab on pre-transplant infection screening will be excluded. Subjects with a positive HBcAb must have negative HBV DNA to be eligible and must be periodically monitored for HBV reactivation by institutional guidelines
Baseline QTcF > 500 milliseconds. This does not apply to subjects with right or left bundle branch blocks
Concurrent active malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix, bladder cancer, or prostate cancer not requiring treatment
Clinically significant medical condition of malabsorption, inflammatory bowel disease, chronic conditions which manifest with diarrhea, refractory nausea,vomiting, or any other condition that will interfere significantly with drug absorption
Concurrent administration of medications or foods that are strong inhibitors or inducers of cytochrome P450 3A (CYP3A). No prior use within 2 weeks before the start of study intervention
Active cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection (i.e., subjects with detectable viral load)
History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or a pacemaker within the last 6 months prior to screening
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or unstable cardiac arrhythmia
Pregnant or breastfeeding
Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended. Recommend exclusion of specific ART agents based on predicted drug-drug interactions (i.e. concurrent strong CYP3A4 inhibitors (ritonavir and cobicistat) or inducers (efavirenz) are contraindicated)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note